Ketamine clinic statistics

Ketamine clinic statistics for 2026, from Spravato rates to patient searches

29 figures on patients, clinics, advertising, Spravato, trials, rules and search demand, each linked to the document that published it. Most were read at source on November 9, 2026.

Get the ketamine AI answer sheet
Trusted by the world's fastest-growing brands

Patients

How many adults live with depression, and how many have tried treatment

National estimates from SAMHSA’s 2024 household survey, and one claims-based count of treatment-resistant depression.

FigureWhat it measuresSource
21.4 millionAdults in the US with a major depressive episode in the past year, 8.2% of all adults, in 2024SAMHSA, 2024 National Survey on Drug Use and Health, released July 28, 2025
14.7 millionAdults whose past-year episode came with severe impairment in 2024, or 5.6% of adultsSAMHSA, 2024 National Survey on Drug Use and Health, released July 28, 2025
64.4%Adults with a past-year major depressive episode who received any mental health treatment during 2024SAMHSA, 2024 National Survey on Drug Use and Health, released July 28, 2025
2.8 millionAdults with treatment-resistant depression in a 12-month period: 30.9% of the 8.9 million whose major depressive disorder was treated with medicationZhdanava and colleagues (Analysis Group and Janssen researchers), Journal of Clinical Psychiatry, March 16, 2021

Treatment-resistant depression is the condition Spravato is approved to treat. None of these four figures counts ketamine patients.

Clinics

Who runs the clinics, and what they offer beyond the infusion chair

One national survey with a website review, and one count of clinics advertising around New York.

FigureWhat it measuresSource
484Community clinics offering ketamine with a public email address, drawn from four clinic databases and surveyed September to November 2023; 119 replies were analyzedPacilio, Parikh and Geller, Journal of Clinical Psychiatry, May 26, 2025
Under 30%Share of 473 clinic websites, read by the same researchers in June 2024, that showed psychiatric physicians running the clinic; nonphysician providers ran over 25%Pacilio, Parikh and Geller, Journal of Clinical Psychiatry, May 26, 2025
Over 80%Surveyed clinics that use maintenance ketamine treatment; over 40% supplied ketamine to take at homePacilio, Parikh and Geller, Journal of Clinical Psychiatry, May 26, 2025
36.5%Clinics that prescribed ketamine for home use, of 233 found advertising it for psychiatric conditions in the New York metropolitan area in 2025Abukahok and colleagues, Fundamental & Clinical Pharmacology, July 2026
94.0%Those 233 clinics that listed depression among the disorders they treat; 21.9% advertised ketamine for substance use disorder, and 51.5% listed a medical doctorAbukahok and colleagues, Fundamental & Clinical Pharmacology, July 2026

The 484 is the survey’s frame, the clinics researchers could email. It is not a census of US clinics, and no census exists.

Advertising and price

What Maryland’s ketamine ads left out, and what an infusion cost

All 17 ketamine advertisers the researchers found operating in Maryland in March 2023, read for claims and prices.

FigureWhat it measuresSource
58.8%Advertisers, 10 of the 17, whose ads never disclosed that the ketamine treatment offered was off-labelCrane, DiStefano and Moore, JAMA Network Open, November 1, 2023
41.1%Advertisers, 7 of the 17, naming no risk at all of adverse effects, addiction or misuse; 3 called ketamine nonaddictive and 1 claimed FDA approval for depression, both falseCrane, DiStefano and Moore, JAMA Network Open, November 1, 2023
$360 to $2,500Listed price of a single infusion, among the 7 of 13 infusion advertisers that put a price onlineCrane, DiStefano and Moore, JAMA Network Open, November 1, 2023

One state in one month. The price range is what those seven clinics listed, not a national average.

Evidence and Spravato

Trial results a page may quote, and how Spravato is given and paid

Two trials with their populations named, then Spravato’s approval, monitoring and Medicare payment.

FigureWhat it measuresSource
55.4% vs 41.2%Patients who responded by three weeks in the ELEKT-D trial, IV ketamine against ECT, among 403 adults with nonpsychotic treatment-resistant depression referred for ECT; self-reported scaleAnand and colleagues, New England Journal of Medicine, June 22, 2023
4.0 pointsGap on the 60-point MADRS after four weeks in Spravato’s Study 1 of 223 adults aged 18 to 64 with treatment-resistant depression: scores fell 19.8 points on Spravato with an antidepressant, 15.8 on placebo with oneSpravato prescribing information, label version 21 on DailyMed, September 24, 2026, section 14.1
March 5, 2019First FDA approval of Spravato and its REMS; use on its own, without an oral antidepressant, for treatment-resistant depression followed in January 2025FDA approval letters for NDA 211243, supplements S-016 and S-027
2 hoursMinimum monitoring at each Spravato session, pulse oximetry included, in a REMS-certified settingSpravato prescribing information, label version 21 on DailyMed, September 24, 2026
$1,356.08Medicare’s 2026 national amount for a Spravato visit above 56 mg (HCPCS G2083), esketamine and two hours of observation included, before geographic adjustmentCMS fee schedule file RVU26D, August 26, 2026: 40.60 RVUs times $33.4009, multiplied by Webzenia
$952.59The same national amount for a visit of 56 mg or less (HCPCS G2082)CMS fee schedule file RVU26D, August 26, 2026: 28.52 RVUs times $33.4009, multiplied by Webzenia

ELEKT-D compared IV ketamine with ECT, not with an antidepressant, and its patients had already been referred for ECT.

Rules and enforcement

Dates, fees and settlements that bear on a clinic’s marketing

Each figure comes from the rule, the order or the fee schedule itself.

FigureWhat it measuresSource
December 31, 2026End of the DEA flexibility for prescribing controlled substances, ketamine among them, by telemedicine with no in-person evaluation; no extension had been published by November 9, 2026DEA rule at 21 CFR 1307.41, extended by 90 FR 61301, Federal Register, December 31, 2025
July 1, 2027Date from which Georgia requires any clinic giving IV ketamine to hold a license from its medical board, under HB 717, signed May 12, 2026Georgia General Assembly, HB 717 (Act 634), 2026 session
June 23, 2026Date of an FDA warning letter to a website selling unapproved and misbranded ketamine lozenges to US consumersFDA warning letter MARCS-CMS 725148, June 23, 2026
Over $7 millionWhat online mental health company Cerebral agreed to pay in April 2024 to settle FTC charges, among them passing the health data of nearly 3.2 million consumers to advertisers through tracking toolsFTC press release on the proposed Cerebral order, April 15, 2024, read through an archived copy
$30,000Settlement paid in 2023 by a New Jersey psychiatry practice whose replies to bad online reviews disclosed patients’ informationHHS Office for Civil Rights announcement, June 5, 2023, from our healthcare research record
$182,000Settlement HHS reached in 2025 with a provider whose website published 150 patients’ success stories with no signed authorizationHHS Office for Civil Rights announcement, September 30, 2025, from our healthcare research record
$3,125First-year LegitScript cost for one website, $975 to apply and $2,150 a year; Google asks it of telemedicine providers and addiction services, Meta of telehealth providers promoting prescription drugsLegitScript, healthcare certification price page, no date shown

A settlement is an agreement, not a court finding. The DEA date and Georgia’s board rules, due by December 31, 2026, are the two figures here most likely to change.

Search demand

What patients search for, and how rarely ads appear

US monthly volumes from Semrush; the two shares are summed across 10,503 searches by Webzenia.

FigureWhat it measuresSource
110,000US searches a month for “ketamine therapy”US keyword volumes from Semrush’s Keyword Magic Tool, October 10, 2026 pull
60.8%Share of monthly patient search volume for ketamine therapy and clinic terms, 349,920 searches in all, on which Google showed an AI OverviewSemrush US database, October 10, 2026, SERP features summed by Webzenia
1.1%Share of that same patient search volume on which Semrush recorded any ad at allSemrush US database, October 10, 2026, SERP features summed by Webzenia
210US searches a month by clinic owners for “ketamine clinic marketing”, with no measured cost per clickUS keyword volumes from Semrush’s Keyword Magic Tool, October 10, 2026 pull

How the figures were chosen

What made this page, and what was kept off it

A figure appears only when its publisher could be read directly and it says no more than that publisher did.

Included

  • Peer-reviewed studies, with each study’s population and dates in the row
  • FDA, DEA, CMS and HHS documents, quoted at the strength of the document
  • Spravato figures and IV ketamine figures in separate rows
  • Semrush counts, labeled with the pull date and Webzenia’s method

Left out

  • Clinic counts and market sizes that name no source or come from paid reports
  • Price roundups from treatment directories whose method is not stated
  • Texas’s proposed ketamine infusion rule, which had not been adopted
  • State bills we could not confirm at their official source

Questions

What the ketamine figures answer, and what they leave open

Short answers, each tied to a row above.

Start here

Put your own consults and treatment starts beside these figures

Name your offices and the treatments each one gives. We ask AI engines the questions patients ask about IV ketamine and Spravato in your metro, and send a dated sheet of the clinics they name.